Absence of pretreatment markers that predict the emergence of YMDD mutants during lamivudine treatment - The results of a prospective multi-center study

Hepato-Gastroenterology

Volumn 53, Issue 67, 2006, Pages 124-127

  Yano, Masahiko ^a   Ohkoshi, Shogo ^a   Suzuki, Kenta ^a   Ito, Shin Ichi ^b   Wakabayashi, Hiroto ^b   Sugiyama, Motoya ^c   Watanabe, Toshiaki ^d   Maeda, Hironobu ^e   Hatakeyama, Shige Aki ^f   Hatano, Tohru ^g   Kobayashi, Yuka ^h   Takei, Shin Ichi ⁱ   Hata, Kohjiro ^j   Tsuboi, Yasunori ^k   Takahashi, Tohru ^l   Ishikawa, Tohru ^m   Kamimura, Tomoteru ^m   Ichida, Takafumi ^a   Aoyagi, Yutaka ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b TAKEDA GENERAL HOSPITAL   (Japan)

^c Ken ritsu Sakamachi Hospital   (Japan)

^d Sanjyo General Hospital   (Japan)

^e Maeda Clinic   (Japan)

^f Hatakeyama Clinic   (Japan)

^g Nagaoka Chu oh Hospital   (Japan)

^h Tachikawa General Hospital   (Japan)

ⁱ Kariwa gun General Hospital   (Japan)

^j National Hospital Organization   (Japan)

^k The Nippon Dental University   (Japan)

^l NAGAOKA RED CROSS HOSPITAL   (Japan)

^m Saiseikai II Hospital   (Japan)

more..

Author keywords

Chronic hepatitis B; Lamivudine; Mutant prediction; YMDD mutant

Indexed keywords

ASPARTIC ACID DERIVATIVE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TYROSYLMETHIONYLASPARTYLASPARTIC ACID; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSPECTIVE STUDY; VIRUS MUTANT; VIRUS STRAIN;

ADULT; AMINO ACID MOTIFS; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33344467648     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC: Inhibition of the replication of hepatitis B virus in vitro by 2', 3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991; 88:8495-8499.
2. Chang CN, Doong SL, Zhou JH, Beach JW, Jeong LS, Chu CK, et al: Deoxycitidine deaminase-resistant stereoisomer is the active form of (+/-)-2', 3' dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem 1992; 267:13938-13942.
3. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M: A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:1657-1661.
4. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al: A one year trial of lamivudine for chronic hepatitis B infection. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-68.
5. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al: Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263.
6. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27:1670-1677.
7. Buti M, Jardi R, Cotrina M, Rodriguez-Frias F, Esteban R, Guardia J: Transient emergence of hepatitis B variants in a patient with chronic hepatitis B resistant to lamivudine. J Hepatol 1998; 28:510-513.
8. Liaw Y-F, Chien R-N, Yeh C-T, Tsai S-L, Chu C-M: Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1990; 30:567-572.
9. Bruno R, Sacchi P, Malfitano A, Filice G: YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient. Gastroenterology 2001; 121:1027-1028.
10. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE: Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28:1032-1035.
11. Liaw YF: Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 2002; Suppl 3:S333-S337.
12. Hadziyannis SJ, Vassilopoulos D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34:617-623.
13. Kramvis A, Kew MC: The core promoter of hepatitis B virus. J Viral Hepat 1999; 6:415-427.
14. Takahashi K, Aoyama K, Ohno N, Iwata K, Akahane Y, Baba K, et al: The precore/core promoter mutation of hepatitis B virus: clinical significance and an easy method of detection. J Gen Virol 1995; 75:3159-3164.
15. Baumert TF, Rogers SA, Hasegawa K, Liang TJ: Two core promoter mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996; 98:2268-2276.
16. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, Okanoue T, Yotsuyanagi H, Iino S: A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33:218-223.
17. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, et al: Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37:19-26.
18. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, et al: Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 1999; 80:97-112.
19. Kobayashi S, Shimada K, Suzuki H, Tanikawa K, Sata M: Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD) motif. Hepatol Res 2000; 17:31-42.
20. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-1520.
21. Kamisango K, Kamogawa C, Sumi M, Goto S, Hirao A, Gonzales F, et al: Quantitative detection of hepatitis B virus by transcription- mediated amplification and hybridization protection assay. J Clin Microbiol 1999; 37:310-314.
22. Stuyver L, Van Geyt C, De Gendt S, Van Reybroeck G, Zoulim F, Leroux-Roels G, et al: Line probe assay for monitoring drug resistance in hepatitis B virus- infected patients during lamivudine therapy. J Clin Microbiol 2000; 38:702-707.
23. Yuen M-F, Sablon E, Hui C-K, Yuan H-J, Decraemer H, Lai C-L: Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001; 34:785-791.
24. Lai CL, Yuen MF: Profound suppression of hepatitis B virus replication with lamivudine. J Med Virol 2000; 6:367-373.
25. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, Hosaka T, et al: The influence of hepatitis B virus geno-type on the development of lamivudine resistance during long-term treatment. J Hepatol 2003; 38:315-321.